Differential inhibitory effects of antidiabetic drugs on arterial smooth muscle cell proliferation

American Journal of Hypertension

Volumn 9, Issue 2, 1996, Pages 188-192

  Peuler, Jacob D ^a,b   Phare, Susan M ^a   Iannucci, Annette R ^a   Hodorek, Mark J ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MIDWESTERN UNIVERSITY   (United States)

Author keywords

antidiabetic agents; diabetes; glyburide; insulin; metformin; pioglitazone; smooth muscle

Indexed keywords

ANTIDIABETIC AGENT; GLIBENCLAMIDE; INSULIN; METFORMIN; PIOGLITAZONE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROSCLEROSIS; CELL PROLIFERATION; CONTROLLED STUDY; DIABETES MELLITUS; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT; SMOOTH MUSCLE FIBER;

EID: 0029871969     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1016/0895-7061(95)00393-2     Document Type: Article

References (15)

1. Sowers J: Insulin resistance, hyperinsulinemia, dyslipidemia, hypertension, and accelerated atherosclerosis. J Clin Pharmacol 1992;32:529-535.
2. Landau C, Lange RA, Hillis LD: Percutaneous transluminal coronary angioplasty. N Engl J Med 1994; 330:981-993.
3. Bunting CE, Koschinsky T, Rütter R, Gries FA: Metformin inhibits the growth of human vascular cells - a new potentially antiatherogenic drug effect (abst). Diabetalogia 1986;29:523A.
4. Dubey RK, Zhang HY, Reddy SR, et al: Pioglitazone attenuates hypertension and inhibits growth of renal arteriolar smooth muscle cells in rats. Am J Physiol 1993;265:R726-R732.
5. Gunther S, Alexander RW, Atkinson WJ, et al: Functional angiotensin II receptors in cultured vascular smooth muscle cells. J Cell Biol 1982;92:289-298.
6. Knorr AM, Kazda S: Influence of nifedipine on experimental arteriosclerosis. Cardiovascular Drugs and Therapy 1990;4:1027-1032.
7. Diglio CA, Grammas P, Giacomelli F, et al: Angiogenesis in rat aorta ring explant cultures. Lab Invest 1989;60:523-531.
8. Caro JF, Ittoop O, Sinha MK: Glyburide but not ciglitazone enhances insulin action in the liver independent insulin receptor kinase activation. Metabolism 1989; 38:606-611.
9. Cavero I, Mondot S, Mestre M: Vasorelaxant effects of cromakalim in rats are mediated by glibenclamide-sensitive potassium channels. J Pharm Exp Ther 1989;248:1261-1268.
10. Kletzien RF, Clarke SD, Ulrich RG: Enhancement of adipocyte differentiation by an insulin sensitizing agent. Mol Pharmacol 1992;41:393-398.
11. Pezzino V, Trischitta V, Purrello F, Vigneri R: Effect of metformin on insulin binding to receptors in cultured human lymphocytes and cancer cells. Diabetologia 1982;23:131-135.
12. Pershadsingh HA, Szollosi J, Benson S, et al: Effects of ciglitazone on blood pressure and intracellular calcium metabolism. Hypertension 1993;21:1020-1023.
13. Purrello F, Gullo D, Brunetti A, et al: Direct effects of biguanides on glucose utilization in vitro. Metabolism 1987;36:774-776.
14. Kobayashi M, Iwanishi M, Egawa K, Shigeta Y: Pioglitazone increases insulin sensitivity by activating insulin receptor kinase. Diabetes 1992;41:476-483.
15. Colca JR, Dailey CF, Palazuk BJ, et al: Pioglitazone hydrochloride inhibits cholesterol absorption and lowers plasma cholesterol concentrations in cholesterol-fed rats. Diabetes 1991;40:1669-1674.